Patents by Inventor Carlo Boutton
Carlo Boutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11312765Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: March 29, 2021Date of Patent: April 26, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220119497Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: April 21, 2022Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Publication number: 20220119512Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: December 27, 2021Publication date: April 21, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11306139Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.Type: GrantFiled: March 18, 2016Date of Patent: April 19, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220099682Abstract: The present invention relates to improved immunogenicity assays and methods for performing the same. In particular, the present invention relates to improved immunogenicity assays that are capable of distinguishing neutralizing anti-drug antibodies from non-neutralizing anti-drug antibodies. More in particular, the present invention relates to improved immunogenicity assays that allow (amounts and/or concentrations of) neutralizing anti-drug antibodies to be detected and/or measured in a sample even in the presence of non-neutralizing anti-drug antibodies.Type: ApplicationFiled: March 29, 2018Publication date: March 31, 2022Applicant: Ablynx N.V.Inventors: Annelies Coddens, Veerle Snoeck, Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220041727Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: October 8, 2021Publication date: February 10, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 11220539Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: December 9, 2020Date of Patent: January 11, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20210403536Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: December 30, 2021Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Publication number: 20210388062Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: December 16, 2021Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Publication number: 20210388061Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: December 16, 2021Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11192937Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: —assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: GrantFiled: June 6, 2017Date of Patent: December 7, 2021Assignee: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11192938Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.Type: GrantFiled: June 6, 2017Date of Patent: December 7, 2021Assignee: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Patent number: 11168136Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: May 17, 2019Date of Patent: November 9, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 11168135Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: May 17, 2019Date of Patent: November 9, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 11155619Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: May 17, 2019Date of Patent: October 26, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Publication number: 20210269515Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 29, 2021Publication date: September 2, 2021Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20210269514Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 29, 2021Publication date: September 2, 2021Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20210261653Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 29, 2021Publication date: August 26, 2021Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20210239709Abstract: The present invention relates to improved immunogenicity assays and methods for performing the same. In particular, the present invention relates to improved immunogenicity assays that are capable of distinguishing neutralizing anti-drug antibodies from non-neutralizing anti-drug antibodies. More in particular, the present invention relates to improved immunogenicity assays that allow (amounts and/or concentrations of) neutralizing anti-drug antibodies to be detected and/or measured in a sample even in the presence of non-neutralizing anti-drug antibodies.Type: ApplicationFiled: March 29, 2018Publication date: August 5, 2021Applicant: Ablynx N.V.Inventors: Annelies Coddens, Veerle Snoeck, Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11021544Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: GrantFiled: February 5, 2016Date of Patent: June 1, 2021Assignee: Ablynx N.V.Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps